Pancreatic cancer is receiving national attention in The Globe and Mail, with a feature story examining both the promise of new targeted therapies and the urgent need for progress in this disease.

The article highlights a critical reality: while breakthroughs like RAS inhibitors are creating meaningful momentum, pancreatic cancer patients remain in a race against time. Most patients are still diagnosed after the disease has already spread, limiting their treatment options and access to emerging therapies.

The story features PCNA CEO Michelle Capobianco, along with PCNA partner and advocate Jen Lovrics, who shares her family's experience after her late husband, Connor Page, participated in a clinical trial of the investigational therapy daraxonrasib.

As Michelle shared with The Globe and Mail:

"The reality, still, is that early detection is the only solution for pancreatic cancer. We're looking for six years, not just six months."

For PCNA, this story reinforces why earlier detection remains our highest strategic priority. Finding pancreatic cancer earlier and treating it more precisely are the greatest opportunities we have to fundamentally improve survival and ensure more patients can benefit from today's breakthroughs and tomorrow's innovations.

We also welcome moments like this because pancreatic cancer has been overlooked for far too long. Greater awareness helps drive research, investment, and collaboration, bringing us closer to a future where pancreatic cancer is detected earlier, treated more precisely, and ultimately survived.

Read the full Globe and Mail article.